In cardiac models of myocardial disease, SMAD2 inhibition protects against cardiac dysfunction, preventing cardiac fibrosis and cardiomyocyte hypertrophy, raising the possible therapeutic options for treating myocardial and valvular disease by targeting canonical TGFβ signaling (55, 56). Here, TGFB1 is linked to myocardial disorder.